VanderbiltHealth.com: For Patients and Visitors
Vanderbilt University Medical Center: For Employees, Researchers, and Students

2010 Publications

1. Basham RJ, Richardson DM, Sutcliffe CB, Haas DW; Effect of HIV-1 infection on human DNA yield from saliva. HIV Clin Trials. 2009 Jul-Aug;10(4):282-5. PMCID: PMC2761620

2. Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman M, Swenson L, Tao I, Szeto S, Rosato P, Sela J, Kadie C, Frahm N, Brander C, Haas DW, Riddler S, Haubrich R, Walker B, Harrigan PR, Heckerman D, Mallal S; HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef Proteins. PLoS One. 2009 Aug 19;4(8):e6687. PMCID: PMC2723923

3. Canter JA, Robbins GK, Selph D, Clifford DB, Kallianpur AR, Shafer R, Levy S, Murdock DG, Ritchie MD, Haas DW, Hulgan T; African Mitochondrial DNA Subhaplogroups and Peripheral Neuropathy during Antiretroviral Therapy. J Infect Dis. 2010 Jun 1;201(11):1703-7. PMCID: PMC2862090

4. Ferreira MAR, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S, Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PIW, Frazer IH, Montgomery GW, Martin NG; Quantitative Trait Loci for CD4:CD8 Lymphocyte Ratio Are Associated with Risk of Type 1 Diabetes and HIV-1 Immune Control. Am J Hum Genet. 2010 Jan;86(1):88-92. Epub 2009 Dec 31. PMCID: PMC2801744

5. Graham BS, McElrath MJ, Keefer MC, Rybczyk K, Berger D, Weinhold KJ, Ottinger J, Ferarri G, Montefiori DC, Stablein D, Smith C, Ginsberg R, Eldridge J, Duerr A, Fast P, Haynes BF, and the AIDS Vaccine Evaluation Group; Immunization with cocktail of HIV-derived peptides in Montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS One. 2010 Aug 10;5(8):e11995. PMCID: PMC2919382

6. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, Garren KW, George T, Rooney JF, Brizz B, Bolivar HH, Goldman M, Haas DW, Mellors JW, Havlir DV; Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009 Aug 24;23(13):1727-9. PMCID: PMC2739977

7. John M, Heckerman D, James I, Park LP, Carlson JM, Chopra A, Gaudieri S, Nolan D, Haas DW, Riddler SA, Haubrich R, Mallal S; Adaptive interactions between HLA and HIV-1: highly divergent selection imposed by HLA class I molecules with common supertype motifs. J Immunol. 2010 Apr 15;184(8):4368-77. PMID: 20231689 [PubMed - indexed for MEDLINE]

8. Ribaudo HJ, Liu H, Schwab M, Schaeffeler E, Eichelbaum M, Motsinger-Reif AA, Ritchie MD, Zanger UM, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford D, Haas DW; Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study. J Infect Dis. 2010 Sep 1;202(5):717-22. PMCID: PMC2919241

9. Spearman P, Kalams S, Elizaga M, Metch B, Chiu YL, Allen M, Weinhold KJ, Ferrari G, Parker SD, McElrath MJ, Frey SE, Fuchs JD, Keefer MC, Lubeck MD, Egan M, Braun R, Eldridge JH, Haynes BF, Corey L; the NIAID HIV Vaccine Trials Network; Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. Vaccine. 2009 Jan 7;27(2):243-249. Epub 2008 Nov 7. PMCID: PMC2692338.

Copyright © 2014 by Vanderbilt University Medical Center    |    1211 Medical Center Drive    |    Nashville, TN 37232    |    (615) 322-5000
Vanderbilt University is committed to principles of equal opportunity and affirmative action.
This page was last updated September 20, 2011 and is maintained by Gina Perez